Rx Product News

Published Online: Friday, July 11, 2014
Follow Pharmacy_Times:

Incruse Ellipta
Marketed by: GlaxoSmithKline
Indication: The FDA has approved Incruse Ellipta (umeclidinium inhalation powder), an anticholinergic, for longterm, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). Incruse Ellipta is for oral inhalation only. The inhaler contains a double-foil blister strip of powder formulation. For maintenance treatment of COPD, 1 inhalation of Incruse Ellipta once daily is recommended.
Dosage Form: Inhalation powder: umeclidinium 62.5 mcg per blister
For More Information: www.gsk.com


Otrexup
Marketed by: Antares Pharma, Inc
Indication: The FDA has approved Otrexup (methotrexate) injection to treat rheumatoid arthritis (RA) and psoriasis in adults, and polyarticular idiopathic arthritis (pJIA) in children. Otrexup is for once-weekly subcutaneous use only and should be administered in the abdomen or thigh. The starting doses are as follows: for RA, 7.5 mg once weekly; for pJIA, 10 mg/ m2 once weekly; for psoriasis, 10 to 25 mg once weekly of an oral, intramuscular, subcutaneous, or intravenous formulation.
Dosage Form: Single-dose autoinjector: 10, 15, 20, or 25 mg
For More Information: www.otrexup.com


Xartemis XR
Marketed by: Mallinckrodt Pharmaceuticals
Indication: The FDA has approved Xartemis XR (oxycodone hydrochloride and acetaminophen) Extended- Release Tablets for the management of acute pain severe enough to require opioid treatment and for which alternative treatment options are inadequate. The recommended dose of Xartemis XR is 2 tablets every 12 hours without regard to food. Tablets should be swallowed whole, and complete swallowing should be ensured immediately after placing them in the mouth.
Dosage Form: Extended-release tablets (oxycodone hydrochloride/acetaminophen): 7.5 mg/325 mg
For More Information: www.xartemisxr.com


Ragwitek
Marketed by: Merck & Co, Inc
Indication: The FDA has approved Ragwitek (short ragweed pollen allergen extract) as immunotherapy for the treatment of short ragweed pollen– induced allergic rhinitis, with or without conjunctivitis, confirmed by positive skin test or in vitro testing for pollen-specific IgE antibodies for short ragweed pollen. Ragwitek is approved for use in adults 18 through 65 years of age. The recommended dosage is 1 tablet daily sublingually.
Dosage Form: Tablets: 12 Amb a 1-unit
For More Information: www.ragwitek.com


Related Articles
In response to a recent resurgence in fentanyl abuse, the DEA today issued a nationwide alert about the dangers of the drug, describing it as a threat to health and public safety.
From optimizing inhaler technique in patients with chronic obstructive pulmonary disease, to catching red flags when dispensing controlled substances to patients with chronic pain, pharmacists can improve patient outcomes in an evolving treatment landscape.
Mylan Inc. has introduced 3 generic versions of existing drugs to the US market, including the first and only available intermediate dosages of transdermal fentanyl.
More than 300 pharmacy students, technicians, and pharmacists helped raise nearly $6500 at the 2015 Mid-Year Conference of the Pennsylvania Pharmacists Association.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$